Previous 10 | Next 10 |
KalVista Pharmaceuticals (KALV) presents data for its oral drug candidates at the European Academy of Allergy and Clinical Immunology ((EAACI)) Congress.Data presentations include Phase 2 data for KVD900 for oral on-demand treatment of hereditary angioedema ((HAE)) attacks. The presented data...
– Phase 2 data for KVD900 in late-breaking session at European Academy of Allergy and Clinical Immunology (EAACI) Congress – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...
DNY59/E+ via Getty Images Shares of KalVista Pharmaceuticals ([[KALV]] -3.8%) are down again today as the shares have shed more than 12% so far this week. BioCryst ([[BCRX]] +1.3%) shares are also down and have lost just over 4% so far this week. The declines are due to pressur...
After edasalonexent's failure last year, Catabasis Pharmaceuticals pivoted to the HAE market through the acquisition of Quellis Biosciences. The acquisition brought QLS-215, a preclinical stage monoclonal antibody with a potentially improved profile compared to prophylactic market lea...
rommma/iStock via Getty Images The shares of KalVista Pharmaceuticals ([[KALV]] -2.9%) came under pressure yesterday after Intellia showed the promise of its technology with first-ever clinical data indicating the safety and efficacy of in-vivo CRISPR gene editing in humans. Intellia...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced acceptance of multiple abstracts at the European Academy of Allergy and Clinical Imm...
KalVista Pharmaceuticals (KALV) announces clinical data supporting KVD900 as an oral on-demand treatment for hereditary angioedema ((HAE)) at the 12th C1-Inhibitor Deficiency & Angioedema Workshop. An analysis of the pharmacokinetic and pharmacodynamic profile of KVD900 and attack symptom...
– KVD900 Efficacious Within First Hours of Attack and Significantly Shortens Time to Improvement of Attack Symptoms – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializa...
KalVista Pharmaceuticals (KALV) has filed for a $300M mixed shelf offering.The filing does not necessarily indicate that a sale has begun, or will occur in the future.KalVista shares closed up 1.8% to $26.07. For further details see: KalVista Pharmaceuticals files for $300M mi...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced acceptance of an abstract for KVD900 as an oral presentation at the 12 th C1-Inh...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...